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Background: There is an ongoing debate on whether patients with chronic obstructive pulmo-
nary disease (COPD) seen in real-life clinical settings are represented in randomized controlled 
trials (RCTs) of COPD. It is thought that the stringent inclusion and exclusion criteria of RCTs 
may prevent the participation of patients with specific characteristics or risk factors.
Methods: We surveyed a database of patients recruited into 35 placebo-controlled tiotropium 
RCTs and also conducted a systematic literature review of large-scale observational studies 
conducted in patients with a documented diagnosis of COPD between 1990 and 2013. Patient 
demographics and comorbidities with a high prevalence in patients with COPD were compared 
between the two patient populations at baseline. Using the Medical Dictionary for Regulatory 
Activities (MedDRA; v 14.0), patient comorbidities in the pooled tiotropium RCTs were clas-
sified according to system organ class, pharmacovigilance (PV) endpoints, and Standardised 
MedDRA Queries to enable comparison with the observational studies.
Results: We identified 24,555 patients in the pooled tiotropium RCTs and 61,361 patients 
among the 13 observational studies that met our search criteria. The Global initiative for chronic 
Obstructive Lung Disease (GOLD) staging of patients in the RCTs differed from that in obser-
vational studies: the proportion of patients with GOLD stages I+II disease ranged from 40.0% 
to 51.5% in the RCTs but 24.5% to 44.1% in the observational studies; for GOLD stage III or 
IV disease these ranges were 7.2%–45.8% (RCTs) and 13.7–42.1% (observational studies). The 
comorbidities with the highest prevalence reported in the RCTs and observational studies were: 
hypertension (39.4%–40.0% vs 40.1%–60.6%), other ischemic heart disease (12.3%–14.2% 
vs 12.5%–41.0%), diabetes (10.3%–10.9% vs 4.0%–38.9%), depression (8.5%–9.5% vs 
17.0%–20.6%), and cardiac arrhythmia (7.8%–11.4% vs 11.3%–15.8%).
Conclusion: The clinical profile of COPD patients treated in the tiotropium trial program 
appears to be largely in the range of clinical characteristics, including cardiovascular comor-
bidities, reported for “real-life patients.” The tiotropium RCTs tended to include patients with 
more severe disease than the observational studies.
Keywords: patient population, baseline characteristics, epidemiology, real-life patients, GOLD 
staging
Introduction
Randomized controlled trials (RCTs) provide the best evidence to support the efficacy 
and safety of therapies and form the basis for regulatory approval of treatment for all 
diseases, including chronic obstructive pulmonary disease (COPD). A well-designed 
RCT has a high degree of internal validity and allows for data-driven determination 
of whether a cause–effect relationship exists between a study drug and its outcome. 
Patient populations in RCTs are subject to stringent inclusion and exclusion criteria, 
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and thus could be perceived as having an inherent lack of 
external validity.1–4 Furthermore, because patients entering 
RCTs are selected, their characteristics and concomitant treat-
ment regimens may not reflect daily clinical practice.5 Ran-
domization and stringency in inclusion and exclusion criteria 
are nevertheless important for determining the comparative 
efficacy and safety of the study drug, limiting the potential 
for confounding and excluding patients at specific risks.
To bridge the gap between RCTs and how medications 
are used by clinicians in daily practice, noninterventional, 
or observational, studies or analyses of existing databases 
are conducted. Unlike RCTs, observational studies normally 
have less stringent inclusion and exclusion criteria and thus 
may provide a broader perspective on disease background, 
comorbid conditions, treatment patterns, and outcomes. 
Observational studies are also more representative of normal 
patterns of care.4 Because they are more representative of 
daily clinical practice, observational studies have high exter-
nal validity and can be generalized,4 but can also be more 
prone to assessment bias1 and outcomes may be confounded, 
in contrast to RCTs.6
According to published epidemiological and obser-
vational studies, some comorbid conditions with a high 
prevalence in patients with COPD include hypertension, 
ischemic heart disease, hypercholesterolemia, diabetes, 
arrhythmias, interstitial lung disease, lung cancer, anxiety, 
and depression.7–12
Based on the ongoing scientific discussion around the 
external validation of RCTs,13–15 we sought to understand how 
representative the patients included in RCTs are to patients in 
a real-life clinical setting, and how the inclusion and exclu-
sion criteria implemented for these trials may have influenced 
the recruited patient population. In particular, it is important 
to know whether patients with comorbidities are adequately 
represented in clinical trials of COPD, or whether they are 
deselected by exclusion criteria – or simply not recruited 
in sufficient numbers. To achieve this goal, we surveyed 
a database of patients recruited into tiotropium RCTs and 
also conducted a systematic literature review of large-scale 
observational studies in order to compare the demography 
and baseline characteristics of the RCT population with 
“real-life” patient populations.
Methods
analysis of tiotropium rCTs
Data on patient baseline characteristics were taken from a 
database (Boehringer Ingelheim GmbH, Ingelheim am Rhein, 
Germany) of 28 placebo-controlled clinical trials conducted 
with a tiotropium HandiHaler® (SPIRIVA®, Boehringer 
Ingelheim GmbH) and seven placebo-controlled trials using 
the tiotropium Respimat® Soft Mist™ Inhaler (SPIRIVA®, 
Boehringer Ingelheim GmbH). The 4-year Understanding the 
Potential Long-term Impacts on Function with Tiotropium 
(UPLIFT®) trial (trial number 205.235) contributed the larg-
est portion of patients to the placebo-controlled HandiHaler® 
database population (Table S1).
Statistical analysis was based on descriptive characteriza-
tion of the pooled trials.
Design of the rCTs in the analysis
Studies were randomized, placebo-controlled, double-blind, 
parallel-group trials of 4 weeks’ duration, assessing either 
tiotropium HandiHaler® 18 µg (once daily) or tiotropium 
Respimat® 5 µg (two puffs of 2.5 µg once daily) for the indi-
cation of COPD. Written informed consent was obtained from 
all patients and ethics committee approval was obtained for 
all protocols. As all trials were part of the tiotropium COPD 
development program, inclusion and exclusion criteria were 
similar across all trials. However, later trials were modified 
to have somewhat broader selection criteria (see inclusion 
and exclusion criteria). Principal patient characteristics like 
age, sex, anthropometrics, and ethnicity were recorded for 
all patients at baseline. Lung function (as measured by forced 
expiratory volume in 1 second [FEV
1
]) and smoking history 
were also captured for the entire population.
Inclusion criteria of the rCTs in the analysis
The key inclusion criteria common to all tiotropium trials 
were: diagnosis of COPD, FEV
1
/forced vital capacity 
ratio 70%, age 40 years, and 10 pack-years’ smoking 
history. Other inclusion criteria such as FEV
1
 cutoffs 
and requirement for exacerbation history varied between 
studies.
exclusion criteria of the rCTs in the analysis
The key exclusion criteria were: diagnosis of asthma, symp-
tomatic prostatic hypertrophy or bladder neck obstruction, 
narrow-angle glaucoma, and known hypersensitivity to the 
study medication or components. For practical reasons, 
significant disease other than COPD that could significantly 
confound the study results or preclude study completion was 
also an exclusion criterion. Other exclusion criteria in earlier 
trial protocols were: heart failure resulting in hospitalization 
in the previous 3 years, cardiac arrhythmia requiring drug 
treatment, or myocardial infarction (MI) within the past year. 
Nevertheless, heart failure and ischemic heart disease were 
not necessarily exclusion criteria. Cardiac exclusion criteria 
were more liberal in more recent trials such as UPLIFT® 
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with HandiHaler® and trial number 205.372 with Respimat® 
(Table S1). Drug therapy for arrhythmias was permitted, pro-
vided the therapy was stable and the patient had no history of 
a life-threatening arrhythmia or pacemaker insertion. In addi-
tion, the criterion for recent MI was decreased to 6 months.
Use of theophylline, inhaled corticosteroids, 10 µg daily 
doses of oral corticosteroids (provided the dosing was stable), 
and short-acting β
2
-agonists was permitted in all trials. The 
4-year UPLIFT® trial (5,992 patients),16 as well as trial 
numbers 205.259,17 205.266 (1,829 patients),18 205.270,19 
205.282,20 205.284,21 205.368,22 and 205.37223 also permitted 
use of long-acting β
2
-agonists (LABAs) as prescribed. 
Nonstudy inhaled anticholinergics had to be withdrawn 
during the conduct of all studies.
Definitions of comorbidities
The Medical Dictionary for Regulatory Activities (MedDRA) 
version 14.0 was used to code relevant medical history/
concomitant diagnoses (within the past 5 years) as reported 
by the investigator at baseline; preferred terms (PTs) were 
categorized under system organ classes (SOCs) within Med-
DRA. For conditions that are known to have a high preva-
lence in patients with COPD, MedDRA PTs denoting similar 
conditions were pooled as pharmcovigilance (PV) endpoints 
and Standardised MedDRA Queries (SMQs).
systematic literature review 
of observational studies
To identify suitable studies, a systematic literature search of 
studies reporting comorbidities among patients with COPD 
was conducted in the following databases: (1) MEDLINE® 
1990, May 14, 2013; (2) BIOSIS Previews® 1993–2008, May 
2013; (3) EMBASE  Alert, May 14, 2013; (4) EMBASE 
1993, May 15, 2013; and (5) SciSearch® 1990, May 2013.
The inclusion and exclusion criteria for the literature 
review are detailed in Figure 1. The inclusion criteria for the 
literature search did not specify how patient demography and 
comorbidity data were presented. It was only important that 
this information be reported. For this reason, the number of 
studies used for the individual analyses will vary.
Results
In total, 17,990 and 6,565 patients were included in the 
HandiHaler® and Respimat® trials, respectively. For the sys-
tematic literature search, using the search parameters detailed 
in the “Methods” section, 806 study publications were returned. 
Following a secondary screen to exclude all studies report-
ing RCTs, hospitalized patient populations, age-restricted 
populations, or reported study populations of fewer than 
900 patients, 793 studies were excluded and 13 epidemiologi-
cal and observational studies12,24–38 (n=61,361 patients) were 
included for comparison with the anthropometrics of patients 
with COPD recruited in tiotropium RCTs (Table S2).
Baseline demographics and clinical 
characteristics
The baseline demographics (Table 1) of the placebo and 
tiotropium groups were balanced between patient popula-
tions in the pooled HandiHaler® and Respimat® trials, with 
34.1%–37.6% of patients enrolled in the tiotropium RCTs 
identified as current smokers, compared with 36.2%–43.0% 
in the observational studies. Patients enrolled in the tiotro-
pium RCTs had a mean baseline post-bronchodilator FEV
1
 
of 1.18±0.47 L standard deviation (SD) and 1.11±0.41 L SD, 
for HandiHaler® and Respimat® trials, respectively, that were 
41.5% and 40.2% of postbronchodilator FEV
1
 predicted, 
for HandiHaler® and Respimat® trials, respectively. In the 
observational studies, the mean baseline post-bronchodilator 
FEV
1
 ranged from 47.0%–56.7% of predicted. The distribu-
tion of patients with COPD enrolled in the tiotropium RCTs 
by Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage was 51.5% and 40.0% (GOLD stages I–II), 
39.8% and 45.8% (GOLD stage III), and 7.2% and 13.6% 
(GOLD stage IV) for HandiHaler® and Respimat® trials, 
respectively. In the comparison observational studies, there 
were more patients enrolled with mild to moderate disease 
(GOLD stage I+II; 24.5%–44.1%), compared with GOLD 
disease stages III or IV (13.7%–42.1%; Table 2).
Although all of the observational studies reported baseline 
comorbidities in the patient population, they differed in how 
this was reported. In some instances, these were reported 
either by SOC or PT. The observational studies also differed in 
the level of additional information reported, relating to patient 
baseline characteristics and baseline concomitant medica-
tions. For this reason, the numbers of studies included in the 
comparisons of these parameters differ in Tables 2–4.
Baseline comorbidities
The majority of patients in the HandiHaler® and Respi-
mat® trials were diagnosed with comorbidities at baseline 
(79.4% and 74.2%, respectively), with vascular and cardiac 
disorders being the most frequent (39.3% and 24.6% in the 
HandiHaler® trials, respectively, and 40.1% and 24.3% in 
the Respimat® trials, respectively) (Table 3). The incidence 
of comorbidities was similar between the placebo and 
tiotropium treatment groups in both sets of trials. In four 
observational studies that enrolled a total of 17,048 patients 
with COPD, associated comorbidities grouped by SOC 
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included cardiac (9.4%–32.3%), vascular (11.4%–45.0%), 
metabolic and nutritional (9.9%–22.2%), and psychiatric 
(11.9%) disorders (Table 3).
For comorbidities that are known to have a high preva-
lence in patients with COPD (hypertension, ischemic heart 
disease, dyslipidemia, diabetes, anxiety, and depression), 
SMQs or PV endpoints were used for the RCTs and 
applicable PTs were grouped to combine endpoints for 
observational studies in order to evaluate their prevalence 
in study populations at baseline (Table 4 and Table S3). 
Figure 1 systematic literature review of observational studies.
Abbreviations: COPD, chronic obstructive pulmonary disease; rCTs, randomized controlled trials.
Databases: 
1) MEDLINE® 1990, May 14, 2013; 2) BIOSIS Previews® 1993–2008, May 2013; 
3) EMBASE Alert, May 14, 2013; 4) EMBASE 1993, May 15, 2013; and 
5) SciSearch® 1990, May 2013. 
Excluded 793 search results reporting:
• RCTs
• Lack of usable comorbidity data
• Hospitalized patient populations 
• Age-restricted (unless within range
of tiotropium RCTs) or reported 
study populations of <900
Included (N=13 results) 
Excluded 13,088 for being:
• Case report(-s), commentary, editorial,
letter(-s), note(-s), population, short
survey, randomized controlled trial,
review(-s)
• Only published in a language other than 
English
• Duplicated results
Analyzed (N=806 results)
Inclusion criteria: 
• All records containing COPD, or Chronic Obstructive within three words 
of Disease, in the title, identifier or descriptor fields
• Published between 2000 and 2013
• Comorbidit(-ies, -y) or Co-Morbidit(-ies, -y) appeared in the title, identifier
or descriptor fields 
• Concomitant within two words of Disease(-s) or Disorder(-s) appeared in
the abstract field 
(N=13,894 results)
Observational studies of COPD that report comorbidities: 2000–2013
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Hypertension was diagnosed in 39.4% of patients in the 
HandiHaler® and 40.0% of patients in the Respimat® trials. 
Diagnoses of ischemic heart disease (14.2% and 12.3%) 
cardiac arrhythmias (7.8% vs 11.4%), depression (9.5% 
vs 8.5%), and diabetes (10.3% vs 10.9%) were similar in 
the pooled HandiHaler® and Respimat® trials, respectively 
(Table 4).
When reported by applicable PTs, the comorbidities with 
the highest prevalence in epidemiological and observational 
studies were hypertension (40.1%–60.6%), cardiac arrhyth-
mia (11.3%–15.8%), depressed mood (17.0%–20.6%), 
cardiac failure (7.0%–49.0%), and ischemic heart dis-
ease (12.5%–41.0%, Table 4). In UPLIFT®, increases in 
comorbid conditions from baseline to year 4 were observed 
(Table S4).
Discussion
We have analyzed the demographic data of patients in ran-
domized, placebo-controlled clinical studies with tiotropium 
HandiHaler® and Respimat® of at least 4 weeks’ duration 
and compared these with data from epidemiological and 
observational studies. The background for this comparison 
was that, recently, several authors questioned the validity of 
RCTs for the evaluation of the safety of drugs in the treatment 
of COPD in clinical practice.13,14 The pivotal argument for 
these concerns was that the inclusion and exclusion criteria 
of RCTs prevent patients at greater risk (notably of cardio-
vascular [CV] risk) from participating in these studies. This 
could then potentially lead to a more positive safety evalua-
tion of the drugs in question compared with clinical practice 
in a real-life setting.
This study of the characteristics of the 24,555 patients 
included in the randomized trials of tiotropium showed that 
the clinical profile, including age, sex, smoking history, and 
anthropometrics of these patients, is similar to that observed 
in large epidemiological and observational studies of patients 
with COPD. However, the proportions of patients with mild 
to moderate disease (GOLD stages I+II) ranged from 24.5% 
to 44.1% in the observational studies but from 40.0% to 
51.5% in the tiotropium trials, while patients with severe 
disease (GOLD stage III or IV) were represented in similar 
numbers in the tiotropium RCTs (7.2%–45.8%) as in the 
observational studies (13.7%–42.1%).
Comorbidities
The most prevalent comorbidities reported by SOC observed 
in the COPD patient population at baseline in the pooled 
tiotropium trials were: cardiac, vascular, respiratory, 
gastrointestinal, psychiatric, and metabolic disorders. These 
were represented in the observational studies in similar pro-
portions (Table 3). In particular, the prevalence of cardiac 
disorders in the 22,916 evaluable patients in the tiotropium 
RCT population was 24.3%–24.6%. Of the 17,048 patients 
with COPD in the epidemiologic/observational studies,21,25,26,30 
the prevalence of cardiac disorders was in the range of 
9.4%–32.3%. In a recent letter to the editor,39 the authors 
conducted an audit of patients discharged from hospital in 
New Zealand after an exacerbation of COPD and found 
that 38% patients prescribed tiotropium had comorbidities 
that would have made them ineligible for participation in 
UPLIFT®. Based on this observation, the authors concluded 
that the findings from UPLIFT® had limited generalizability 
to clinical practice in New Zealand. However, this New 
Zealand patient population is a very severe population of 
patients that required hospital admission, whereas patients 
included in UPLIFT®, as in all major clinical trials of COPD, 
consisted of ambulatory patients. The pattern of comorbidi-
ties of very severe admitted patients may differ, but this New 
Zealand patient population represents a minority of patients 
with COPD of special severity with increased risks of side 
effects secondary to all drugs and that require a personalized 
approach with careful evaluation of the expected benefits and 
risks of any given treatment.
Although it was excluded from our systematic literature 
review because it is a pooled analysis of epidemiological 
studies, validation of the current analysis is provided by 
a study conducted by Patel and Hurst.40 Using data from 
two large, population-based epidemiological studies (the 
Atherosclerosis Risk in Communities [ARIC] Study and 
the Cardiovascular Health Study [CHS], 20,296 adults 
aged 44 years),40 they reported that the prevalence of CV 
disease (defined as a composite of ischemic heart disease, 
heart failure, stroke, and/or transient ischemic attack) in 
patients with COPD was 20.0%–22.0%. This is similar to 
the 24.6% and 24.3% prevalence of cardiac disorders that 
we determined in the tiotropium trials. This contradicts the 
concerns that the inclusion and exclusion criteria of tiotro-
pium RCTs prevent patients at greater risk (notably of CV 
risk) from participating in these studies.
Comorbidities of interest were selected on the basis of 
being the most frequently reported in COPD trials and also to 
maximize the degree of comparisons with the observational 
studies identified in our systematic literature review. For 
eight selected comorbidities of interest (Table 4), our analy-
sis revealed that hypertension had the highest prevalence 
in patients enrolled in tiotropium RCTs (39.4%–40.0%). 
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This was lower than the range (51.4%–60.6%) reported in 
four out of nine observational studies26,28,32,35,36 (total: 6,884 
patients) used in our comparison. However, in a population-
based National Institutes of Health cohort of 20,296 patients 
with COPD aged 45 years, the prevalence of hyperten-
sion was 40.1%,32 similar to that reported for patients in 
tiotropium RCTs.
Although not included in our current analysis because 
it is not among the most frequently reported comorbidities 
among patients with COPD, two reports, by Verhamme 
et al41 and Mathioudakis et al,42 have suggested an asso-
ciation between mortality and renal impairment in patients 
with COPD treated with tiotropium via HandiHaler® or 
Respimat®. A pooled safety analysis of tiotropium delivered 
via the HandiHaler® or the Respimat® Soft Mist™ Inhaler 
that encompasses 22 Phase III and IV tiotropium clinical 
trials and evaluated 10,805 patients showed that that there 
was no trend for increased incidence rate ratios of adverse 
events with worsening renal function for either tiotropium 
HandiHaler® or Respimat®. (Table S5).43
limitations of the study
A major limitation of this study is the difference in the report-
ing of baseline characteristics and comorbidities in the obser-
vational studies identified in our systematic literature review. 
Only six of the observational studies reported the GOLD 
staging of patients. Although included in this comparison, 
Mannino et al’s study32 reports GOLD staging for only 27.1% 
of the patients enrolled, which complicates interpretation of 
these results. Furthermore, four studies reported baseline 
comorbidities by SOC, and none of these allowed for a full 
comparison with the tiotropium RCTs. This means that for 
comorbidities such as respiratory, thoracic and mediastinal 
disorders, gastrointestinal disorders, psychiatric disorders, 
and neoplasms, the patient population against which the 
tiotropium RCT population is compared is limited (only 2,846 
from two of the four observational studies as compared with 
22,916 in the tiotropium RCTs combined). This variability 
complicates interpretation of these results due to the limited 
sample size. Although this situation is repeated for compari-
son of baseline comorbidities in Table 4, it is mitigated to 
some extent by the inclusion of 51,050 patients from nine 
out of 13 observational studies for comparison to the 22,916 
patients identified in the included tiotropium RCTs.
Another limitation of this study is that it does not take 
into account the various factors that add to the complexity 
of studying comorbidities in patients with COPD. These 
include: smoking status, which has been shown to be a 
risk factor for diabetes mellitus and dyslipidemia; age; 
polypharmacy; lack of treatment of comorbidities; and lack 
of specific case definitions for comorbidities.7 However, with 
regard to smoking status, the percentage of current smokers 
enrolled in the tiotropium RCTs is similar to the percentage 
identified as current smokers in the observational studies 
included in our analysis.
Lastly, patients with recent unstable cardiac diseases (MI 
within 6 months and new unstable arrhythmia or severe heart 
failure within 1 year) were excluded from the tiotropium 
RCTs. Therefore, the findings in the tiotropium studies can-
not be extended to these patients.
Conclusion
The clinical profile (defined by SOC) of patients with 
COPD treated in the tiotropium trial program appears to 
be largely in the range of clinical characteristics, including 
CV comorbidities reported for “real-life patients.” Overall, 
patients in the tiotropium studies were comparable to those 
patients enrolled in the observational studies with regard to 
the severity of disease (GOLD stages III and IV).
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Table S1 Clinical trials included in the pooled tiotropium handihaler® and respimat® analysis
Boehringer Ingelheim 
trial number
Trial duration 
(weeks)
Placebo-treated 
patients (N)
Tiotropium-treated 
patients (N)
Reference
HandiHaler® trials
205.114/117 48 191 279 Casaburi et al1
205.115/128 48 180 271 Casaburi et al1
205.123 (eClIPse®) 6 40 81 agusti et al2
205.124 4 30 65 Mcnicholas et al3
205.130 24 201 209 Brusasco et al4
205.131 6 100 98 O’Donnell et al5
205.137 24 199 193 Brusasco et al4
205.214 (MIsTral) 48 510 500 Dusser et al6
205.215 12 54 46 Verkindre et al7
205.218 4 41 40 Celli et al8 and Maltais et al9
205.223 6 130 131 Maltais et al9
205.230 25 53 55 Casaburi et al10
205.235 (UPlIFT®) 210 3,006 2,986 Tashkin et al11
205.247 25 117 117 Kesten et al42
205.256 (TIPhOn) 36 288 266 Tonnel et al12
205.257 12 403 1,236 Beeh et al13
205.259 (saFe) 48 305 608 Chan et al14
205.266 24 915 914 niewoehner et al15
205.269 16 127 123 Powrie et al16
205.270 52 73 69 Powrie et al16
205.276 (sPrUCe) 12 195 200 Freeman et al17
205.281 12 117 107 Johansson et al18
205.282 (saFe Portugal) 12 164 147 Moita et al19
205.284 12 96 100 Covelli et al20
205.294 8 86 80 Criner et al21
205.301 12 244 228 Magnussen et al22
205.365 24 219 238 sciurba et al23
205.368 (eXaCTT) 96 259 260 Cooper et al24
Respimat® trials
205.251/252 12 181 180 Voshaar et al25
205.254/255 52 653 670 Bateman et al26
205.372 52 1,965 1,952 Bateman et al27
1,205.4 4 55 53 littner et al28
1,205.14 24 429 427 abrahams et al29
Note: Trial numbers refer to the Boehringer Ingelheim trials database.
Abbreviations: eClIPse, evaluation of COPD longitudinally to Identify Predictive surrogate endpoints; eXaCTT, exercise endurance and COPD Treated With Tiotropium; 
MISTRAL, Mesure de l’Influence de SPIRIVA® sur les Troubles Respiratoires Aigus à Long terme [measuring the influence SPIRIVA® on acute respiratory disorders for the 
long term]; saFe, sPIrIVa® assessment of FeV1; sPrUCe, sPIrIVa
® Usual CarE; TIPHON, Tiotropium: Influence sur la Perception de l’amelioration des activités Habituelles 
Objectivée par une echelle Numerique; UPLIFT®, Understanding the Potential long-term Impacts on Function with Tiotropium; COPD, chronic obstructive pulmonary 
disease.
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